Cheng M, Li J, Negri A, Coller B. Swing-out of the ?3 hybrid domain is required for ?IIb?3 priming and normal cytoskeletal reorganization, but not adhesion to immobilized fibrinogen. PLoS ONE. 2013;8:e81609 pubmed 出版商

Choi W, Rice W, Stokes D, Coller B. Three-dimensional reconstruction of intact human integrin ?IIb?3: new implications for activation-dependent ligand binding. Blood. 2013;122:4165-71 pubmed 出版商

Murcia M, Jirouskova M, Li J, Coller B, Filizola M. Functional and computational studies of the ligand-associated metal binding site of beta3 integrins. Proteins. 2008;71:1779-91 pubmed 出版商

Blue R, Murcia M, Karan C, Jirouskova M, Coller B. Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen. Blood. 2008;111:1248-56 pubmed

Jirouskova M, Jaiswal J, Coller B. Ligand density dramatically affects integrin alpha IIb beta 3-mediated platelet signaling and spreading. Blood. 2007;109:5260-9 pubmed

Mitchell W, Li J, Murcia M, Valentin N, Newman P, Coller B. Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation. Blood. 2007;109:3725-32 pubmed

Nelson E, Li J, Mitchell W, Chandy M, Srivastava A, Coller B. Three novel beta-propeller mutations causing Glanzmann thrombasthenia result in production of normally stable pro-alphaIIb, but variably impaired progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi. J Thromb Haemost. 2005;3:2773-83 pubmed

Mitchell W, Li J, Singh F, Michelson A, Bussel J, Coller B, et al. Two novel mutations in the alpha IIb calcium-binding domains identify hydrophobic regions essential for alpha IIbbeta 3 biogenesis. Blood. 2003;101:2268-76 pubmed

Basani R, French D, Vilaire G, Brown D, Chen F, Coller B, et al. A naturally occurring mutation near the amino terminus of alphaIIb defines a new region involved in ligand binding to alphaIIbbeta3. Blood. 2000;95:180-8 pubmed

Dangas G, Badimon J, Coller B, Fallon J, Sharma S, Hayes R, et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol. 1998;18:1342-9 pubmed

Grimaldi C, Chen F, Wu C, Weiss H, Coller B, French D. Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa. Blood. 1998;91:1562-71 pubmed

Grimaldi C, Chen F, Scudder L, Coller B, French D. A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia. Blood. 1996;88:1666-75 pubmed

Reverter J, Beguin S, Kessels H, Kumar R, Hemker H, Coller B. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest. 1996;98:863-74 pubmed

Kutok J, Coller B. Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: requirement for antibody bivalency. Thromb Haemost. 1994;72:964-72 pubmed